SUMO2

Small ubiquitin-related modifier 2 · P61956 · SUMO2 on Sugi Atlas →

9,443 patent compounds predicted against SUMO2, 5,599 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3958375 SCHEMBL3958375 1.00 7/20
SCHEMBL2622737 SCHEMBL2622737 0.56 7/20
SCHEMBL1712890 SCHEMBL1712890 0.58 6/20
SCHEMBL3915968 SCHEMBL3915968 0.71 5/20
SCHEMBL110923 SCHEMBL110923 0.60 5/20
SCHEMBL110924 SCHEMBL110924 0.60 5/20
SCHEMBL1436156 SCHEMBL1436156 0.60 5/20
SCHEMBL1436155 SCHEMBL1436155 0.59 5/20
SCHEMBL3487054 SCHEMBL3487054 0.57 5/20
SCHEMBL414245 SCHEMBL414245 0.52 5/20
SCHEMBL3714721 SCHEMBL3714721 0.51 5/20
SCHEMBL3714723 SCHEMBL3714723 0.51 5/20
SCHEMBL3433588 SCHEMBL3433588 0.44 5/20
SCHEMBL3423417 SCHEMBL3423417 0.41 5/20
SCHEMBL3427611 SCHEMBL3427611 0.38 5/20
SCHEMBL2592201 SCHEMBL2592201 1.00 4/20
SCHEMBL2592202 SCHEMBL2592202 1.00 4/20
SCHEMBL2587118 SCHEMBL2587118 0.73 4/20
SCHEMBL2593909 SCHEMBL2593909 0.73 4/20
SCHEMBL2587651 SCHEMBL2587651 0.72 4/20

Clinical trials — most relevant to SUMO2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1) PHASE3NOT_YET_RECRUITING
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine PHASE2/PHASE3WITHDRAWN
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines. PHASE1WITHDRAWN
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level nanENROLLING_BY_INVITATION
MEHMO Natural History and Biomarkers nanRECRUITING
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Genetic Analysis to Predict the Development of Paget's Disease nanACTIVE_NOT_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Expression and Clinical Significance of IGHD in Pancreatic Cancer nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Molecular Profile of the Evolution of Inclusion Body Myositis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SUMO2 binder may also engage these)

ProteinNameSimilarity
P61959 1.000 P61959 →
Q2PFW2 1.000 Q2PFW2 →
P61957 1.000 P61957 →
Q6LDZ8 1.000 Q6LDZ8 →
Q6DHL4 1.000 Q6DHL4 →
Q7ZTK7 1.000 Q7ZTK7 →
Q28H04 1.000 Q28H04 →
Q6DK72 1.000 Q6DK72 →
Q7SZ22 1.000 Q7SZ22 →
A7WLI0 1.000 A7WLI0 →
Q6GPW2 1.000 Q6GPW2 →
Q6NV25 1.000 Q6NV25 →
SUMO3 Small ubiquitin-related modifier 3 (SUMO-3) ( 1.000 landscape →
Q6DI05 1.000 Q6DI05 →
Q5ZJM9 1.000 Q5ZJM9 →
P61958 1.000 P61958 →
P61955 1.000 P61955 →
Q12306 1.000 Q12306 →
Q6EEV6 0.999 Q6EEV6 →
Q5ZHQ1 0.999 Q5ZHQ1 →
Q5XIF4 0.998 Q5XIF4 →
P55852 0.993 P55852 →
G2XKQ0 0.992 G2XKQ0 →
Q9FLP6 0.992 Q9FLP6 →
Q3E8A8 0.991 Q3E8A8 →
O13351 0.988 O13351 →
B3H5R8 0.988 B3H5R8 →
Q17QV3 0.987 Q17QV3 →
Q9Z172 0.986 Q9Z172 →
P55857 0.978 P55857 →